Five anti-core glycolipid monoclonal antibodies (MAb) (four against Escherichia coli J5 lipopolysaccharide [LPS] and one against the Re core glycolipid of Salmonella typhimurium) were characterized using LPS from several rough and smooth strains and derivatives of E. coli J5 LPS, obtained by N acetylation and hydrolysis.
Antibodies raised against the rough mutant (R mutant) Escherichia coli J5 have been reported to protect against infections caused by gram-negative bacteria (19, 21, 24) . Neutralization of the endotoxins (lipopolysaccharides [LPS] ) by these antibodies has been postulated (23) , but against which epitope of LPS these antibodies are directed is not known. E. coli J5 LPS is of chemotype RcP+, and its inner core contains glucosamine, glucose, heptose, 3-deoxy-D-manno-octulosonic acid (KDO), phosphate, phosphoethanolamine, ethanolamine, and lipid A. Among members of the family Enterobacteriaceae, the structure of the inner core is highly conserved. However, E. coli J5 LPS is heterogenous and contains several molecular species ( Fig. 1) (12) . Additionally, a D-glucosaminyl-(a-1-7)-L-glycero-D-manno-heptose disaccharide is linked as a branch to the basal core structure (6, 12) . Because E. coli J5 LPS is heterogenous, antibodies with different binding sites are induced after immunization. Some of these anti-E. coli J5 antibodies show cross-reactivity with other gram-negative clinical isolates, and some do not (9, (14) (15) (16) . The most immunogenic part of the E. coli J5 LPS appears to be the nonreducing terminal sugar of the core region: glucose linked to heptose (6) . It is not yet known to which epitope(s) the antibodies in crossprotective antisera are directed.
Only with chemically characterized E. coli J5 LPS is it possible to elucidate the antigenic binding site of antibodies on a molecular level. With the help of monoclonal antibodies (MAb) reactive with different antigenic determinants, it may then be possible to define the epitope that has the capacity to induce cross-protective antibodies in animals and humans. We have produced several MAb against the R mutants E. coli J5 and Salmonella typhimurium (5) . These By using gas-liquid chromatography-mass spectrometry, a glucose-heptose or heptose-glucose disaccharide could be detected in dialysates 2 and 3 after methylation by the method of Hakomori (10) . Analysis (2, 12) of the preparations after 0.1 M acetate buffer and HCl hydrolysis showed loss of KDO, phosphate, and glucosamine, in agreement with the contents of the dialysates. The sediment after HCl treatment (J5 LPS-HCl) did not contain KDO but did have neutral sugars. Thus, even after HCl hydrolysis the lipid A part was not split off completely from the core, as was expected from results described before with LPS of other R strains (4, 8) .
Kinetic hydrolysis. Samples of E. coli J5 LPS (2 mg/ml) in 0.1 M HCl at 100°C were taken at 0, 15, 30, and 60 min, neutralized with NaOH to pH 7.0, and kept at -20°C. The phosphate release was measured in the supernatant after centrifugation (10 min, 2,500 x g) by the method of Lowry et al. (13) , in which almost all of the J5 LPS was sedimented.
LPS-HF. LPS were dephosphorylated twice with 48% hydrogen fluoride (LPS-HF) for 48 h at 4°C. After adjustment with NaOH (1 N) to pH 5 to 7, the solution was dialyzed and lyophilized (yield, 70%). LPS-HF was dephosphorylated for at least 95% as determined by phosphate analysis (12) . LPS-NAc. LPS (200 ,ul, 5 mg/ml) were N acetylated (LPS-NAc) with 50 ,ul of saturated NaHCO3 and 2 ,ul of acetic acid anhydride, with continuous stirring for 30 min at room temperature. After dialysis against aquadest the solution was lyophilized. Analysis of the E. coli J5 LPS-NAc with gas-liquid chromatography-mass spectrometry showed that no detectable degradation products were formed.
Deamination of LPS. E. coli J5 LPS (200 ,ll, 5 mg/ml) was deaminated by treating with 2 ml of NaNO2 (5%) and 2 ml of acetic acid (33%). This mixture was stirred for 1 h at room temperature, passed through an ion-exchange column (Amberlite H+ IR 120), and washed three times with water. The eluate was dialyzed and lyophilized. The degree of deamination was tested by screening the dialysate after reduction for anhydromannitol (product of deaminated glucosamine, released after hydrolysis) by using gas-liquid chromatography-mass spectrometry. At least 25% (wt/wt) of original glucosamine was measured as anhydromannitol.
LPS-OH. E. coli J5 LPS (1 g) was de-O acetylated (LPS-OH) by drying under reduced pressure in the presence of P205 and stirred for 15 h at 37°C with 15 ml of anhydrous sodium methylate (0.25 M). After centrifugation the sediment was dissolved in 5 to 10 ml of water, and LPS-OH was precipitated with 60 to 80 ml of ethanol, centrifuged (10 min, 1,400 x g, 4°C), and dried (yield, 90%). LPS-OH was analyzed as described previously (12) . It contained only half the original amount of 3-hydroxy-myristic acid. Nonhydroxylated fatty acids (12:0, 14:0) were absent, and there was no indication for changes in the amounts of other constituents. LPS-OH contained, as expected, two amide-linked 3-OH myristic acids, which were resistant to this alkali treatment.
MAb. ELISA. The enzyme-linked immunosorbent assay (ELISA) was performed as previously described (5) on polyvinylchloride microdilution plates with horseradish peroxidase-conjugated anti-IgG and anti-IgM and detected with tetramethylbenzidine. Microdilution plates were coated with lipid A (0.1 ml per well, 5 ,ug/ml) in aquadest (adjusted to pH 7.0 with triethylamine) and cooled to 4°C. Cold HCl (25 ,ul, 0.4 N) was added, and the lipid A was precipitated for 15 to 30 min at 4°C. The plates were centrifuged (600 x g, 5 min, 4°C) and then washed with cold 0.01 N HCl for 15 min at 4°C. After centrifugation, the plates were washed with water and 0.05% Tween 20, and the ELISA procedure was followed as usual. Wells were coated with LPS (100 Pld) diluted in PBS to 1 ,ug/ml or with bacteria (100 ,ul, adjusted to 2.5 x 108 bacteria per ml in PBS). Plates were incubated for 1 h at 37°C and overnight at 4°C.
Inhibition ELISA. Antibodies (diluted to a concentration that gave an optical density of 1.0 after reaction with the antigen used) were preincubated with decreasing amounts of antigen as serial twofold dilutions in microdilution plates (PBS-0.05% Tween 20) for 30 min at 37°C. The inhibited antibody solutions were tested in a normal ELISA and compared with uninhibited antibodies, except that the antigen-coated plates were first incubated with 4% bovine serum albumin, PBS, and 0.05% Tween 20 for 1 h at 37°C to block unbound plastic. The amount of antigen that gave an optical density of 50% compared with that of uninhibited antibodies was called the inhibitory amount, measured in nanograms.
Competition ELISA. E. coli J5 LPS (0.1 ml, 1 ,ug/ml)-coated microtiter plates were incubated after thoroughly washing with decreasing amounts of an IgG MAb for 1 h at 37°C in 4% bovine serum albumin-PBS-0.05% Tween 20. After washing, the plates were incubated with a competitive IgM MAb, adjusted to a dilution that produced an optical density of about 1 buffer) were then added, and the plates were incubated for 1 h at 37°C. After incubation, the plates were centrifuged (3 min, 600 x g, 4°C), and the hemolytic titer could easily be read with the naked eye. The hemolytic titer was defined as the antibody dilution that gave 50% lysis. A hemolytic unit was defined as the dilution that was one twofold dilution step before the dilution with the hemolytic titer.
Inhibition PHT. MAb (25 RI) was added to the potential inhibitor (LPS antigens) (twofold serial dilutions, 25 p1l) in microdilution plates. After gentle mixing the plates were incubated for 15 min at 37°C. Antigen coated on SRBC and complement was added, and the test was performed as described above. The inhibitory concentration was then read with the naked eye. The lowest amount of inhibitor that was just sufficient to give complete inhibition (no lysis) was expressed in nanograms.
RESULTS AND DISCUSSION Reaction with bacteria, LPS, and lipid A. The reactivity of the MAb was tested against the clinical isolates in an ELISA; only the MAb raised against Re LPS (8-2C1) reacted with all clinical isolates tested. The anti-J5 LPS MAb 4-7B5 showed some weak reactions against S. marcescens, E. cloacae, E. coli 0135 K+, P. mirabilis, and M. morganii. The other anti-J5 LPS MAb did not react with any of the clinical isolates (data not shown). Also, the reactivity of the MAb against various LPS preparations, chemically modified E. coli J5 LPS, and the hydrolyzed fractions J5 LPS (Table  1) was tested in the ELISA (Table 2 ) and in the inhibition PHT ( Only the reactivity between MAb BA7 and J5 LPS-coated SRBC was strongly decreased after deamination of E. coli J5 LPS (resulting in release of glucosamine). Therefore, it appeared that a glucosamine with a free amino group is essential for binding with MAb BA7. This conclusion is supported by the finding that E. coli LPS-NAc also failed to bind MAb BA7. These latter two derivatives of E. coli J5 LPS reacted in a similar fashion with the other three MAb. reactivity decrease. It appears that hydrolysis in acetate buffer did not effectively cleave E. coli J5 LPS in core and lipid A. J5 LPS-ACB appeared to consist of E. coli J5 LPS in which some molecules were devoid of phosphorylated oligosaccharides. The four MAb could still bind to their antigenic determinants, even though the reaction of the four MAb with J5 LPS-HCL was diminished, because most sugars present in the core region and all KDO were cleaved.
The amount of Pi released during kinetic hydrolysis of E. coli J5 LPS (0.1 N HCl, 100°C) (Fig. 2) was compared with acid-labile phosphate substitution. It is possible that the glucosamine-heptose disaccharide is cleaved off during HCI hydrolysis and that therefore less reactivity with MAb BA7 could be seen in this experiment. For MAb 4-6A1 and MAb 4-7B5 the phosphate substitution is less important. Hydrolysis of sugar-sugar bonds, which form important antigenic binding sites, was responsible for the loss in their reactivity. MAb 4-6A1 probably binds to the heptose residues in the inner core, and these bonds may be more resistant to hydrolysis.
Competition experiment with MAb 4-7B5 and 4-6A1. E. coli J5 LPS-coated microdilution plates were incubated with twofold dilutions of MAb 4-6A1; after washing, the plates were incubated with the competitive MAb 4-7B5 (diluted 1:10,000 or 1:20,000) (Fig. 3A) and with MAb 4-6A1 as the competitive antibody (Fig. 3B) . The amounts of MAb 4-7B5 (IgM; Fig. 3A ) and of MAb 4-6A1 (IgG; Fig. 3B) were measured with labeled anti-IgM and anti-IgG, respectively. These competition experiments show that MAb 4-7B5 has more affinity to E. coli J5 LPS than does MAb 4-6A1. The proposed binding sites of the four MAb against E. coli J5 LPS are summarized in Fig. 4 .
From the lack of activity of MAb 4-9A1 with LPS of the Ra, Re, and R5 types, dephosphorylated E. coli J5 LPS, and the products after kinetic hydrolysis of E. coli J5 LPS, we concluded that MAb 4-9A1 reacts with the terminal part of the core region, glucosyl-1,3-heptose, in which the heptose residue is probably phosphorylated. During hydrolysis of E. coli J5 LPS with HCI (0.1 N), the reactivity of MAb 4-9A1 is quickly lost. The glucose-1,3-heptose and the phosphateheptose linkages are sensitive to HCI hydrolysis. Lack of binding of MAb 4-9A1 to Ra can be explained by the fact that the glucose-1,3-heptose is substituted on glucose and therefore sterically hindered in these LPS forms.
Because of lost activity after deamination and N acetylation of E. coli J5 LPS, we conclude that MAb BA7 reacts with glucosamine with a free amino group linked (al-7) to heptose in the core region. The glucosaminyl-heptose has not been previously described as a constituent of LPS of S. typhimurium and Salmonella minnesota strains, and we therefore suggest that the antigenic binding site of BA7 is the glucosaminyl-heptose disaccharide. MAb BA7 showed no reactivity with LPS of Vibrio cholerae, which also contains this disaccharide (6, 12) . This could be due to a different antigenic exposition. In contrast to anti-lipid A-KDO MAb 8-2C1, the anti-E. coli J5 LPS core oligosaccharide MAb (4-9A1, 4-6A1, and BA7) were not cross-reactive with gram-negative clinical isolates. This finding is supported by recent publications (1, 17, 21) , which also suggest that reactivity of MAb with lipid A and/or KDO confers broad cross-reactivity and that reactivity of Rc/J5 specific MAb does not (20) . The cross- 
